Bendamustine Hydrochloride Patent Expiration

1. Belrapzo patent expiration

BELRAPZO's oppositions filed in EPO
BELRAPZO IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8791270 EAGLE PHARMS Bendamustine pharmaceutical compositions
Jan, 2026

(1 year, 5 months from now)

US11872214 EAGLE PHARMS Formulations of Bendamustine
Jan, 2031

(6 years from now)

US11103483 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US10010533 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US11844783 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US9265831 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US9572796 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US9572797 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US8609707 EAGLE PHARMS Formulations of bendamustine
Aug, 2031

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
ODE*(ODE*) Dec 07, 2022

Market Authorisation Date: 15 May, 2018

Treatment: For the treatment of patients with indolent b-cell non-hodgkin lymphoma; For the treatment of patients with chronic lymphocytic leukemia

Dosage: SOLUTION

How can I launch a generic of BELRAPZO before it's drug patent expiration?
More Information on Dosage

BELRAPZO family patents

Family Patents

2. Bendeka patent expiration

BENDEKA's oppositions filed in EPO
BENDEKA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8791270 EAGLE PHARMS Bendamustine pharmaceutical compositions
Jan, 2026

(1 year, 5 months from now)

US8791270

(Pediatric)

EAGLE PHARMS Bendamustine pharmaceutical compositions
Jul, 2026

(1 year, 11 months from now)

US11844783 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US11103483 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US11872214 EAGLE PHARMS Formulations of Bendamustine
Jan, 2031

(6 years from now)

US9265831 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US9572797 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US9572796 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US10010533 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(6 years from now)

US8609707 EAGLE PHARMS Formulations of bendamustine
Aug, 2031

(7 years from now)

US9597399 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(8 years from now)

US9000021 EAGLE PHARMS Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
Mar, 2033

(8 years from now)

US9572887 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(8 years from now)

US9579384 EAGLE PHARMS Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
Mar, 2033

(8 years from now)

US9034908 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(8 years from now)

US9597398 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(8 years from now)

US9597397 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(8 years from now)

US10052385 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(8 years from now)

US9144568 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-179) Dec 07, 2022

Market Authorisation Date: 07 December, 2015

Treatment: For use in treatment of patients with chronic lymphocytic leukemia (cll) and/or non-hodgkin's lymphoma; For the treatment of patients with chronic lymphocytic leukemia; For the treatment of patients w...

Dosage: SOLUTION

How can I launch a generic of BENDEKA before it's drug patent expiration?
More Information on Dosage

BENDEKA family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Treanda patent expiration

TREANDA's oppositions filed in EPO
TREANDA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8445524 CEPHALON Solid forms of bendamustine hydrochloride
Mar, 2029

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8791270 CEPHALON Bendamustine pharmaceutical compositions
Jan, 2026

(1 year, 5 months from now)

US8609863 CEPHALON Bendamustine pharmaceutical compositions
Jan, 2026

(1 year, 5 months from now)

US8895756 CEPHALON Bendamustine pharmaceutical compositions
Jan, 2026

(1 year, 5 months from now)

US8791270

(Pediatric)

CEPHALON Bendamustine pharmaceutical compositions
Jul, 2026

(1 year, 11 months from now)

US8895756

(Pediatric)

CEPHALON Bendamustine pharmaceutical compositions
Jul, 2026

(1 year, 11 months from now)

US8609863

(Pediatric)

CEPHALON Bendamustine pharmaceutical compositions
Jul, 2026

(1 year, 11 months from now)

US8883836 CEPHALON Solid forms of bendamustine hydrochloride
Mar, 2029

(4 years from now)

US9533955 CEPHALON Solid forms of bendamustine hydrochloride
Mar, 2029

(4 years from now)

US8669279 CEPHALON Solid forms of bendamustine hydrochloride
Mar, 2029

(4 years from now)

US8344006 CEPHALON Liquid formulations of bendamustine
Sep, 2029

(5 years from now)

US8883836

(Pediatric)

CEPHALON Solid forms of bendamustine hydrochloride
Sep, 2029

(5 years from now)

US8445524

(Pediatric)

CEPHALON Solid forms of bendamustine hydrochloride
Sep, 2029

(5 years from now)

US8669279

(Pediatric)

CEPHALON Solid forms of bendamustine hydrochloride
Sep, 2029

(5 years from now)

US9533955

(Pediatric)

CEPHALON Solid forms of bendamustine hydrochloride
Sep, 2029

(5 years from now)

US8344006

(Pediatric)

CEPHALON Liquid formulations of bendamustine
Mar, 2030

(5 years from now)

US8436190 CEPHALON Bendamustine pharmaceutical compositions
Oct, 2030

(6 years from now)

US8436190

(Pediatric)

CEPHALON Bendamustine pharmaceutical compositions
Apr, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-580) Oct 31, 2011
New Chemical Entity Exclusivity(NCE) Mar 20, 2013
Pediatric Exclusivity(PED) May 01, 2016
Orphan Drug Exclusivity(ODE) Oct 31, 2015
ODE*(ODE*) Dec 07, 2022

NCE-1 date: 02 May, 2015

Market Authorisation Date: 13 September, 2013

Treatment: For use in the treatment of patients with chronic lymphocytic leukemia and/or non-hodgkins lymphoma; For use in the treatment of patients with chronic lymphocytic leukemia (cll) and/or indolent b-cell...

Dosage: POWDER; SOLUTION

How can I launch a generic of TREANDA before it's drug patent expiration?
More Information on Dosage

TREANDA family patents

Family Patents

4. Vivimusta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11844784 SLAYBACK PHARMA LLC Stable pharmaceutical compositions of bendamustine
Jul, 2042

(18 years from now)




Market Authorisation Date: 07 December, 2022

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

VIVIMUSTA family patents

Family Patents